Journal
BULLETIN DU CANCER
Volume 108, Issue 4, Pages 359-368Publisher
ELSEVIER MASSON, CORP OFF
DOI: 10.1016/j.bulcan.2020.11.022
Keywords
Pituitary tumour-transforming 3; Castration-resistant prostate cancer; MiR-146a-3p; Pituitary tumour transforming gene 1
Categories
Funding
- Incubation Project Grant from The Third Affiliated Hospital (General Hospital) of Chongqing Medical University [KY08033]
- Science and Technology Research Program of Chongqing Municipal Education Commission [KJQN201800404]
Ask authors/readers for more resources
In this study, overexpression of PTTG3P in CRPC cells was found to promote resistance to androgen-deprivation therapy by upregulating PTTG1 through a competitive mechanism. This suggests that PTTG3P may serve as a potential target for therapy of CRPC.
Bockground > Overexpression of certain long non-coding RNAs (lncRNAs) promotes the progression of castration-resistant prostate cancer (CRPC). The significance and potential role of the IncRNA designated pituitary tumour-transforming 3, pseudogene (PTTG3P) in CRPC is unknown. Methods > We detected PTTG3P expression by qPCR. Upregulated PTTG3P expression was performed to explore the role of PTTG3P in PCa cells resistant to ADT (androgen deprivation therapy). The relationship among PTTG3P, mir-146a-3p and PTTG1 were validated by qPCR, western blot and luciferase assay. Results > PTTG3P levels were significantly increased in the androgen-independent PC cell lines, as well as in CRPC tissues compared with those of the androgen-dependent prostate cancer cell line LNCaP and tumour tissues of patients with hormone-naive prostate cancers. Enforced expression of PTTG3P in androgen-deprived LNCaP cells significantly enhanced survival, clonogenicity, and tumorigenicity. Further, PTTG3P acted as a competing endogenous RNA (ceRNA, natural miRNA sponge) to upregulate PTTG1 expression by competing for mir-146a-3p in the progression to CRPC. Conclusion > Our findings suggest that PTTG3P promotes the resistance of prostate cancer cells to androgen-deprivation therapy via upregulating PTTG1. PTTG3P may therefore represent a potential target for therapy of CRPC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available